NEWS AND EVENTS

November 2022         

AJK Biopharmaceutical published  " Broad-spectrum antibacterial activity alone and in combination with antibiotics." J. Med. Chem. 2022, (SEE DETAILS)

September 2022         

AJK Biopharmaceutical Team Participate in World AMR (Antimicrobial Resistance) Congress

August  2022              

NIH Awarded a Gant to AJK Biopharmaceutical for “ Development of Broad-Spectrum Cyclic Amphiphilic Peptides against Multidrug-Resistant Bacteria.

April 2022                   

AJK Biopharmaceutical filed a patent "   Synthetic Antimicrobial peptides, US Patent App. 17/639,082, 2022. (SEE DETAILS)        

March  2022               

AJK Biopharmaceutical published "Amphiphilic cyclic peptide [W 4 KR 5]-antibiotics combinations as broad-spectrum antimicrobial agents. Eur. J. Med. Chem., 2022, 17, 235:114278. DOI:10.1016/j.ejmech.2022.114278. PMID: 35347995.     

November 2021         

AJK Biopharmaceutical filed a patent " Compositions and methods for nucleic acid delivery.PCT Int. Appl. (2021), WO 2021134026 A2 20210701.

October 2021               

AJK Biopharmaceutical published " Small Amphiphilic Peptides: Activity Against Broad Range of Drug-Resistant Bacteria and Structural Insight into Membranolytic Properties. J. Med. Chem. 2022, 65, 665-687. doi:10.1021/acs.jmedchem.1c01782. PMID: 34978443.

August 2021                 

AJK Biopharmaceutical filed a patent "Amphiphilic peptides for nucleic acid and protein delivery. August 4, 2021, US 63/229,149 "

April 2021                     

AJK Biopharmaceutical filed a patent "  Synthetic antimicrobial peptides PCT Int. Appl. (2021), WO 2021042039 A1 20210304.(SEE DETAILS)

Feb 2021                     

AJK Biopharmaceutical published " Synthesis and antiviral activity of fatty acyl conjugates of Remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus. European Journal of Medicinal Chemistry, 2021, 226, 113862, (SEE DETAILS).

May 2020                   

AJK Biopharmaceutical published " Comparative antiviral activity of Remdesivir and anti-HIV nucleoside analogs against human coronavirus 229E (HCoV-229E). Molecules (2020) 25(10), 2343; ( SEE DETAILS )